Keywords
How to Cite
Abstract
Annotatsion. From 60 years old increased at least every hundredth male this disease with gets sick. From 70 years old then every eighth male this to illness exposed Metastatic to hormones resistant prostate cancer in treatment chemotherapy both in monoregime and in other drugs with together application todays on the day standard is considered. Many in cases prostate cancer hormonal androgen deprivation therapy (therapeutic castration) is good answer Unfortunately, time to pass with many in patients treatment continue to the extent despite, tumor develop Testosterone begins. decrease in malignant cells growth stop for enough This situation will not happen. to the hormone resistant to hormone resistant or to castration resistant prostate It is called cancer. Treatment the results improve for medicines, their combinations and prostate with breast cancer sick patients for new therapy modes search continue is doing.
References
1. 1. Samoylik B. M. Epidemiological aspects of cancer pre-state symptoms in Krasnodar region for the period from 2000 to 2009. Materialy V Kongressa Rossiyskogo obshchestva endourologic. 2010. URL: http://www.roou.ru/.uploads/press/tezis/292/5_ Congress_Oncourology-inet27.fi le27.fi le.pdf
2. Chissov V. I., Rusakov I. G. Заболеваемост раком предстательной железы в Российской Федерации. Experimental and clinical urology. 2011. No. 2-3. URL: http://www.ecuro.ru/journal/number-2-3-2011.
3. Engalychev F. Sh., Mironov M. A., Galkina N. G., Lyamkin S. V. Statisticheskie dannye po raku predstatelnoy zhelely v Penzenskoy oblasti za 2005-2009 gody. Materialy V Kongressa Rossiyskogo obshchestva onkourologov . 2010. URL : http :// www . rooo ru /. uploads / press / thesis /292/5_ Congress _ Oncourology - inet 27. file 27. fi le .pdf
4. Karyakin O. B. Sovremennye podkhody k lecheniyu hormonreziszentnogo raka predstatelnoy zheleny. Oncourology . 2011. No. 1. S.101-107.
5. Apolikhin O. I., Katibov M. I., Shaderkin I. A. Puti standardizatsii okazaniya etapnoy pomoshchi patientam s rakom prestatelnoy signs and RF. Experimental and clinical urology. 2011. No. 2-3. URL: http://www.ecuro.ru/journal/number2-3-2011.
6. H eidenreich A., Bolla M., Joniau S., Kwast TH, Matveev V., Mason M. D, Mottet N., Schmid H.-P., Wiegel T., Zattoni F. Rekomendatsii po lecheniyu raka predstatelnoy zheleny. Evropeyskaya association Urologist . URL: http://www.uroweb.org/fi leadmin / tx_eauguidelines /2009/Full/ru_3_Prostate_Cancer.pdf
7. T annok I. et al.; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351: 1502–1512. 23. De Bono J. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364 , 1995–2005 (2011).
8. Fizazi K. et al. Final overall survival (OS) analysis of COU-AA301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer ( mCRPC ) pretreated with docetaxel. Presented at the European Multidisciplinary Cancer Congress ECCO. Stockholm, Sweden 23–27 September 2011. EJC Volume 47 Supplement 2, September 2011, LBA1. 25. Fleming M. et al., Results of a randomized phase II study of mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy. Journal of Clinical Oncology
9. Abstract number 4555 (2010). 26. B erger E. et al. Results of a randomized phase II study of irofl uven in hormone-refractory prostate cancer patients who have failed fi rst - line docetaxel treatment. American Society of Clinical Oncology Genitourinary Cancers Symposium. Abstract number: 5068. 2007.
10. R osenberg J. et al., Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007 Aug 1;110(3):556-63. 28. de Bono J. et al., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. 29. T he Cochrane Handbook for Systematic Reviews of Interventions. Chapter 8: Assessing risk of bias in included studies. URL: http://www.cochrane-handbook.org/
11. T annock I. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 14, 1756-1764 (1996). 31. BarryW . et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 168 , 2439 - 2443 (2002).
12. Goryainov S. V., Rebrova O. Yu. Indirect comparison of direct medical technology// Medical technology. Otsenka and vybor . 2011. No. 3(5 ). S. 9-12. 33. Glenny A. et al., Indirect comparisons of competing interventions. Health Technol Assess. 2005 Jul;9(26):1-134, iii-iv. 34. B ucher H. et al., The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol . 1997 Jun;50(6): 683-91.
13. Yagudina R. I., Kulikov A. Yu., Arinina E. E. Pharmacoeconomics and oncology. M .: Izdatelstvo " Shiko ", 2011. 424 p .: il . 36. Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol . 2011 Apr;7(4):497-506.